Introduction: 18F-2-Fluoro-2-deoxyglucose (18F-FDG) in addition to Prostate Specific Membrane Antigen (PSMA) PET has been employed to assess the eligibility for PSMA-targeted therapy by some centers.
Introduction: 18F-PSMA-1007 PET is used in the management of patients with prostate cancer. However, recent reports indicate a high rate of non-specific bone uptake (NSBU) with 18F-PSMA-1007, which may lead to false positive diagnosis.
Resection of tumor lesions using targeted dual-modality probes combining preoperative imaging with intraoperative guidance is of high clinical relevance and might considerably impact the outcome of prostate cancer therapy.
The clinical introduction of (68)Ga-PSMA-11 ("HBED-CC") ligand targeting the prostate-specific membrane antigen (PSMA) has been regarded as a significant step forward in the diagnosis of prostate cancer (PCa).
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
